About Michael Bell

This author has not yet filled in any details.
So far Michael Bell has created 10 blog entries.
12 Jan, 2018

Pre-Analytical Assessment of Circulating Cell-Free DNA Prepared by An Isolation-Free Enrichment Technology

Publication: ACTA Scientific Cancer Biology Volume 2 Issue 1 January 2018 Abstract Quantity and quality of circulating cell-free DNA (cfDNA) from plasma is highly variable, with frequent contamination of larger, genomic DNA as a consequence [...]

3 Jan, 2018

CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory

CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory Company expands single-blood-tube, cancer-targeted therapy and immunotherapy testing to parts of Europe, Africa, the Middle East and Commonwealth of Independent States (CIS) [...]

29 Nov, 2017

CIRCULOGENE Appoints Dr. Glen J. Weiss as Chief Medical Officer

BIRMINGHAM, Ala. ­­­– CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, has named medical oncologist and cancer researcher Glen J. Weiss, M.D., MBA, as Chief Medical Officer. Dr. Weiss will oversee and advance the [...]

17 Nov, 2017

Circulogene Featured in Genetic Engineering & Biotechnology News

November 15, 2017 Circulogene's Chen-Hsiung Yeh, Ph.D., CSO, was recently featured in a new article titled, Cell-Free DNA Drives Liquid Biopsy Testing published by Genetic Engineering & Biotechnology News. "Chen-Hsiung Yeh, Ph.D., CSO, Circulogene Theranostics, believes that what makes [...]

15 Nov, 2017

CIRCULOGENE Introduces Single-Tube, Blood-Based Microsatellite Instability (MSI) Biomarker Testing for Multiple Cancers

MSI Diagnostic Testing Available for Precision Cancer Immunotherapy BIRMINGHAM, Ala.--(BUSINESS WIRE)-- CIRCULOGENE, a leading liquid biopsy company advancing precision medicine through personalized molecular genetics testing, has announced the availability of microsatellite instability (MSI) biomarker testing for [...]

20 Apr, 2016

AACR 2016 Research Shows Circulogene Liquid Biopsy Excels at Real-Time Monitoring of Cancer Mutations

AACR 2016 Research Shows Circulogene Liquid Biopsy Excels at Real-Time Monitoring of Cancer Mutations Interlab comparison demonstrates Circulogene’s blood-drop-volume liquid biopsy assay is fastest, most accurate process to date for tracking and treating cancer BIRMINGHAM, Ala., – [...]

10 Nov, 2015

Circulogene Launches Liquid Biopsy Product Into Market

Proprietary Finger-Stick Cancer Monitoring Technology Launches Circulogene Theranostics into Liquid Biopsy Market Breakthrough, cell-free DNA testing method enables fast, accurate, personalized cancer monitoring and treatment guidance with a single blood drop BIRMINGHAM, Ala., November 10, [...]

17 Aug, 2015

Circulogene Highlighted on WBHM Magic City Marketplace

Rachel Lindley of WBHM's Magic City Marketplace and Cindy Fisher Crawford, Editor, Birmingham Business Journal, discuss the latest news from the week of August 18, 2015. In this week's events, Crawford breaks the latest news [...]

14 Aug, 2015

Circulogene Theranostics Featured in Birmingham Business Journal

Birmingham Business Journal reported on Birmingham's latest breakthrough biotechnology company, Circulogene Theranostics and their recent surge of local investment. The article includes interviews with Mike Mullen, CEO and President, Dr. Chen Hsiung-Yeh, Chief Scientific Officer, [...]

27 Jul, 2015

Next-Generation Sequencing and Targeted Cancer Therapy

MOJ Cell Science & Report published an editorial written by Circulogene's Chief Scientific Officer, Dr. Chen-Hsiung Yeh, on Next-Generation Sequencing and Targeted Cancer Therapy. The complex nature of cancer and the transformation of cancer care, [...]